Deltex acquires Medicina's TECO

13 February 2006

The UK's Deltex Medical Group, an Altenative Investment Market-listed hemodynamic monitoring company, says that it has acquired the TECO esophageal Doppler monitor business from Medicina for an undisclosed sum.

Medicina Limited is a UK medical device company focused on marketing enteral feeding equipment. Since the early 1990s, it has developed and marketed an esophageal Doppler monitor system, the TECO. This uses a re-usable ultrasound probe, which is covered by a disposable single-use sheath. Up to three hundred TECO monitors have been installed in hospitals around the world, with the largest bases established in Ireland, China, the UK and India.

Deltex Medical has agreed to acquire the intellectual property rights to the TECO system together with all stocks of devices and accessories. To meet the cost of the acquisition and to provide finance for the subsequent integration of the TECO system, the company has placed with institutional and other investors 1,030,000 new ordinary shares of 1 pence each at 20 pence per share to raise L200,000 of cash after expenses. Application will be made for the new shares to be traded on the AIM and it is expected that dealings will commence on February 14.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight